585 related articles for article (PubMed ID: 27059609)
21. Novel therapeutic approaches in multiple system atrophy.
Palma JA; Kaufmann H
Clin Auton Res; 2015 Feb; 25(1):37-45. PubMed ID: 24928797
[TBL] [Abstract][Full Text] [Related]
22. FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy.
Kragh CL; Fillon G; Gysbers A; Hansen HD; Neumann M; Richter-Landsberg C; Haass C; Zalc B; Lubetzki C; Gai WP; Halliday GM; Kahle PJ; Jensen PH
PLoS One; 2013; 8(1):e55243. PubMed ID: 23372841
[TBL] [Abstract][Full Text] [Related]
23. β-III Tubulin fragments inhibit α-synuclein accumulation in models of multiple system atrophy.
Suzuki Y; Jin C; Iwase T; Yazawa I
J Biol Chem; 2014 Aug; 289(35):24374-82. PubMed ID: 25028513
[TBL] [Abstract][Full Text] [Related]
24. Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies.
Kisos H; Pukaß K; Ben-Hur T; Richter-Landsberg C; Sharon R
PLoS One; 2012; 7(10):e46817. PubMed ID: 23077527
[TBL] [Abstract][Full Text] [Related]
25. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease.
Marmion DJ; Rutkowski AA; Chatterjee D; Hiller BM; Werner MH; Bezard E; Kirik D; McCown T; Gray SJ; Kordower JH
Neurobiol Dis; 2021 Jan; 148():105184. PubMed ID: 33221532
[TBL] [Abstract][Full Text] [Related]
26. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies.
Refolo V; Bez F; Polissidis A; Kuzdas-Wood D; Sturm E; Kamaratou M; Poewe W; Stefanis L; Angela Cenci M; Romero-Ramos M; Wenning GK; Stefanova N
Acta Neuropathol Commun; 2018 Jan; 6(1):2. PubMed ID: 29298733
[TBL] [Abstract][Full Text] [Related]
27. Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions.
Kaji S; Maki T; Ishimoto T; Yamakado H; Takahashi R
Transl Neurodegener; 2020; 9():7. PubMed ID: 32095235
[TBL] [Abstract][Full Text] [Related]
28. Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death.
Tsuboi K; Grzesiak JJ; Bouvet M; Hashimoto M; Masliah E; Shults CW
Mol Cell Neurosci; 2005 Jun; 29(2):259-68. PubMed ID: 15911350
[TBL] [Abstract][Full Text] [Related]
29. Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.
Stemberger S; Poewe W; Wenning GK; Stefanova N
Exp Neurol; 2010 Aug; 224(2):459-64. PubMed ID: 20493840
[TBL] [Abstract][Full Text] [Related]
30. Microtubule depolymerization suppresses alpha-synuclein accumulation in a mouse model of multiple system atrophy.
Nakayama K; Suzuki Y; Yazawa I
Am J Pathol; 2009 Apr; 174(4):1471-80. PubMed ID: 19286568
[TBL] [Abstract][Full Text] [Related]
31. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy.
Heras-Garvin A; Weckbecker D; Ryazanov S; Leonov A; Griesinger C; Giese A; Wenning GK; Stefanova N
Mov Disord; 2019 Feb; 34(2):255-263. PubMed ID: 30452793
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological inhibition of FABP7 by MF 6 counteracts cerebellum dysfunction in an experimental multiple system atrophy mouse model.
Cheng A; Jia W; Finkelstein DI; Stefanova N; Wang H; Sasaki T; Kawahata I; Fukunaga K
Acta Pharmacol Sin; 2024 Jan; 45(1):66-75. PubMed ID: 37605049
[TBL] [Abstract][Full Text] [Related]
33. Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications.
Schafferer S; Khurana R; Refolo V; Venezia S; Sturm E; Piatti P; Hechenberger C; Hackl H; Kessler R; Willi M; Gstir R; Krogsdam A; Lusser A; Poewe W; Wenning GK; Hüttenhofer A; Stefanova N
PLoS One; 2016; 11(3):e0150705. PubMed ID: 26962858
[TBL] [Abstract][Full Text] [Related]
34. Binding of neuronal α-synuclein to β-III tubulin and accumulation in a model of multiple system atrophy.
Nakayama K; Suzuki Y; Yazawa I
Biochem Biophys Res Commun; 2012 Jan; 417(4):1170-5. PubMed ID: 22227187
[TBL] [Abstract][Full Text] [Related]
35. Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
Papay R; Zuscik MJ; Ross SA; Yun J; McCune DF; Gonzalez-Cabrera P; Gaivin R; Drazba J; Perez DM
J Neurochem; 2002 Nov; 83(3):623-34. PubMed ID: 12390524
[TBL] [Abstract][Full Text] [Related]
36. Higher levels of myelin phospholipids in brains of neuronal α-Synuclein transgenic mice precede myelin loss.
Grigoletto J; Pukaß K; Gamliel A; Davidi D; Katz-Brull R; Richter-Landsberg C; Sharon R
Acta Neuropathol Commun; 2017 May; 5(1):37. PubMed ID: 28482862
[TBL] [Abstract][Full Text] [Related]
37. Alpha-synuclein transgenic mice: relevance to multiple system atrophy.
Fillon G; Kahle PJ
Mov Disord; 2005 Aug; 20 Suppl 12():S64-6. PubMed ID: 16092093
[TBL] [Abstract][Full Text] [Related]
38. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.
Stefanova N; Kaufmann WA; Humpel C; Poewe W; Wenning GK
Acta Neuropathol; 2012 Jul; 124(1):51-65. PubMed ID: 22491959
[TBL] [Abstract][Full Text] [Related]
39. Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy?
Stefanova N; Hainzer M; Stemberger S; Couillard-Després S; Aigner L; Poewe W; Wenning GK
Exp Neurol; 2009 Sep; 219(1):368-71. PubMed ID: 19460374
[TBL] [Abstract][Full Text] [Related]
40. Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications.
Kaindlstorfer C; Sommer P; Georgievska B; Mather RJ; Kugler AR; Poewe W; Wenning GK; Stefanova N
Neurotox Res; 2015 Oct; 28(3):185-94. PubMed ID: 26194617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
